When does this change take effect?

This change is effective Apr 30, 2025.

CommercialCoverageMedium impact

08.01.47a, Triamcinolone Acetonide Extended-Release Injectable (Zilretta®)

Q: Who is affected by this change?

This affects Independence Blue Cross Orthopedics, Rheumatology, Pain Management, PM&R (Physical Medicine & Rehab) providers on Commercial plans.

Independence Blue Cross·Orthopedics, Rheumatology, Pain Management +1 more·Pharmacy

Effective date

Apr 30, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Insurance policy 08.01.47a for Triamcinolone Acetonide Extended-Release Injectable (Zilretta®) has been reissued for commercial plans. This is a pharmacy policy update that will take effect April 30, 2025.

Action Required

Action needed

By April 30, 2025: Billing team should review the full policy details at the source URL to understand any changes to coverage or billing requirements for Zilretta® injections. Monitor for updated prior authorization requirements or documentation needs for this extended-release triamcinolone acetonide injectable.

Related policy hubs

Independence Blue Cross policies Orthopedics Rheumatology Pain Management PM&R (Physical Medicine & Rehab)